Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484484 | 1.00 | NAAA (0.51) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL3485068 | 1.00 | NAAA (0.51) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL7872593 | 0.88 | NAAA (0.51) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL7872594 | 0.88 | NAAA (0.51) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL31375607 | 0.87 | NAAA (0.46) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL10672051 | 0.85 | NAAA (0.44) | NAAAIDO1TDO2PREPTSHR | |
| SCHEMBL31628107 | 0.85 | LMNA (0.49) | NAAAIDO1TDO2PREPALDH1A1 | |
| SCHEMBL8166405 | 0.81 | HSD17B10 (0.46) | ALDH1A1TSHR | |
| SCHEMBL8136446 | 0.81 | HSD17B10 (0.46) | ALDH1A1TSHR | |
| SCHEMBL7485886 | 0.81 | HSD17B10 (0.46) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2010-06-10 | — | — | US | disclosed |
| US-6316413-B1 | HETEROCYCLIC OLIGOPEPTIDE DERIVATIVES | FOURNIER INDUSTRIE ET SANTE (FR) | 2001-11-13 | — | — | US | disclosed |
| EP-0948524-A1 | PEPTIDES AGONISTS OF BRADYKININE B 2? RECEPTOR | FOURNIER INDUSTRIE ET SANTE (FR) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998024809-A1 | PEPTIDES AGONISTS OF BRADYKININE B2 RECEPTOR | FOURNIER INDUSTRIE ET SANTE (FR) | 1998-06-11 | — | — | WO | disclosed |
| US-5618808-A | Benzothiazepine and benzoxazepine derivatives as cholecystokinin receptor antagonists | PFIZER, INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0648213-A1 | BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| WO-1994001421-A1 | BENZOTHIAZEPINE AND BENZOXAZEPINE DERIVATIVES AS CHOLECYSTOKININ RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | TRPV1, TRPV4, CACNA1B | NAAA 1971/4885IDO1 1829/4885TDO2 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.